N/A
N=31,265
HPV Vaccine Communication ECHO for Primary Care Clinics
Human Papillomavirus Vaccines · Adolescent Health Services
Bottom Line
View on ClinicalTrials.gov: NCT04587167 ↗Enrolled (actual)
31,265
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: HPV Vaccination (≥1 Dose), 11-14 Year Olds at 12 Months — 3189; 3833; 4260 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Project ECHO (Other); Announcement Approach Training (Other); Recall notices (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Milton S. Hershey Medical Center
- Primary completion
- Sep 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY HPV Vaccination (≥1 Dose), 11-14 Year Olds at 12 Months |
3189; 3833; 4260 | — |
| SECONDARY HPV Vaccination (≥1 Dose), 11-14 Year Olds at 3 Months |
2483; 1759; 4083 | — |
| SECONDARY HPV Vaccination (≥1 Dose), 11-14 Year Olds at 6 Months |
2584; 1831; 4177 | — |
| SECONDARY HPV Vaccination (≥1 Dose), 11-14 Year Olds at 9 Months |
2744; 1888; 4102 | — |
| SECONDARY HPV Vaccination (Completion), 11-14 Year Olds at 3 Months |
1517; 1063; 3075 | — |
| SECONDARY HPV Vaccination (Completion), 11-14 Year Olds at 6 Months |
1655; 1156; 3249 | — |
| SECONDARY HPV Vaccination (Completion), 11-14 Year Olds at 9 Months |
1817; 1232; 3180 | — |
| SECONDARY HPV Vaccination (Completion), 11-14 Year Olds at 12 Months |
1984; 1946; 3432 | — |
| SECONDARY HPV Vaccination (≥1 Dose), 15-17 Year Olds at 3 Months |
1965; 1801; 3182 | — |
| SECONDARY HPV Vaccination (≥1 Dose), 15-17 Year Olds at 6 Months |
1976; 1805; 3158 | — |
| SECONDARY HPV Vaccination (≥1 Dose), 15-17 Year Olds at 9 Months |
1997; 1812; 3185 | — |
| SECONDARY HPV Vaccination (≥1 Dose), 15-17 Year Olds at 12 Months |
2397; 3684; 3176 | — |
| SECONDARY HPV Vaccination (≥1 Dose), 11-14 Year Olds at 12 Months by Sex |
1628; 1860; 2079; 1561; 1973; 2181 | — |
| SECONDARY HPV Vaccination (≥1 Dose), 15-17 Year Olds at 12 Months by Sex |
1210; 1846; 1585; 1187; 1838; 1591 | — |
Summary
The safe, highly-effective human papillomavirus (HPV) vaccine remains underused in the US; only 51% of 13- to 17-year-old girls and boys were up-to-date by 2018. The Announcement Approach Training is effective in increasing HPV vaccine uptake during the clinic visit by training providers to make strong vaccine recommendations and answer parents' common questions. Systems communication like recall notifications also improve vaccination by reducing missed clinical opportunities. Although never tested to support HPV vaccination, the ECHO (Extension for Community Healthcare Outcomes) Model is a proven implementation strategy to promote capacity exchange between health care experts at academic centers and primary care providers at the front line of rural community health care. The trial will test the effectiveness of two ECHO-delivered HPV vaccination communication interventions versus control: HPV ECHO will provide Announcement Approach training, and HPV ECHO+ will provide training plus recall notices to communicate with parents who initially decline vaccination.
Eligibility Criteria
Clinics in cluster RCT (main study)
Inclusion Criteria
- Family medicine or pediatric clinic in Pennsylvania
- Having at least 100 active patients, ages 11-14.
Exclusion Criteria
- Primary care clinic outside Pennsylvania
- Participated in HPV vaccine communication or quality improvement research either through Penn State or another institution in the last 12 months.
Parents in nested study survey
Inclusion criteria
- Parent or guardian of an adolescent ages 11-17
- Adolescent has not yet started HPV vaccination
- Adolescent receive primary care at participating clinic
Exclusion criteria
- Not the parent or guardian of an adolescent ages 11-17
- Adolescent already initiated HPV vaccination
- Adolescent does not receive primary care at participating clinic
Data sourced from ClinicalTrials.gov (NCT04587167). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.